GAITHERSBURG, Md., Oct. 15, 2021 — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Vivek Shinde, M.D., Vice President, Clinical Development, will deliver a presentation during the World Vaccine Congress Europe 2021. A topic of discussion will be Novavax’ COVID-NanoFlu™ Combination Vaccine, which combines the company’s recombinant nanoparticle protein-based COVID-19 and NanoFlu™ vaccine candidates with Matrix-M™ adjuvant in a single formulation.
Session details are as follows:
| Date: | Wednesday, October 20, 2021 |
| Time: | 11:30 a.m. – 12:00 p.m. Central European Time (CET) / 5:30 a.m. – 6:00 a.m. Eastern Daylight Time (EDT) |
| Title: | Update on Novavax’ NanoFlu vaccine and COVID-19-NanoFlu Combination Vaccine development |
| Novavax Participant: | Vivek Shinde, M.D., Vice President, Clinical Development |
